Oxidation-reduction drug and dye · Fact sheet
Methylene blue
Also known as Methylthioninium chloride · ProvayBlue
Methylene blue has an FDA-approved product for acquired methemoglobinemia, a blood oxygen-transport disorder. Small cognitive studies do not establish a general nootropic or anti-aging benefit, and serious drug interactions are a central concern.
What is Methylene blue?
Methylene blue is a redox-active small molecule and dye. Evidence for a regulated medical product cannot be transferred to technical dyes or unverified wellness preparations.
Benefits & claims
Mental clarity, memory, energy, and mitochondrial support drive interest. These claims concern different populations and outcomes from the approved blood-disorder indication.
What the evidence supports
- ProvayBlue treats acquired methemoglobinemia in its labeled medical setting.
- Small experiments found selected memory effects, but no dependable evidence of everyday cognitive enhancement or longer life.
Research areas
- Acquired methemoglobinemia
- Memory tasks
- Fear-extinction learning
Dosage & frequency
Product-specific label informationProvayblue is an intravenous emergency medicine for acquired methemoglobinemia. Its weight-based label does not establish an oral nootropic regimen.
Provayblue
Adults and pediatric patients with acquired methemoglobinemia
- Amount
- 1 mg/kg; one repeat dose after one hour may be considered under labeled criteria
- Frequency
- One monitored administration, with a possible second dose
- Route studied or labeled
- Intravenous
Emergency treatment over 5–30 minutes; renal impairment can limit repeat dosing.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
Formulation differences
- Pharmaceutical methylene blue is distinct from nonmedical dye preparations.
Interactions & precautions
- The boxed warning addresses serious serotonin syndrome with serotonergic medicines and opioids; G6PD deficiency is a contraindication.
What is still unresolved
- A safe and effective repeated oral cognitive-enhancement regimen remains unestablished.
Side effects & risks
- The label has a boxed warning about serious or fatal serotonin syndrome with serotonergic medicines and opioids.
- G6PD deficiency is a contraindication because of hemolysis risk; severe allergy is also a concern.
- Discoloration, headache, nausea, and altered taste are among reported effects. Pregnancy and lactation carry specific label precautions.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Early human evidenceThe cognitive evidence includes a 26-person healthy-adult imaging study and a 42-person fear-learning study. Both are small and context-specific; this grade describes the frontier claims, not denial of the approved medical use.
Studies
26-person randomized experiment; short-term task and imaging outcomes.
42-person claustrophobia experiment; outcomes depended on successful versus unsuccessful exposure learning.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
Explore 3 sourced accounts by reported effect.
Energy: reported experiences
Calmer mood, clearer thinking and deeper sleep
A separate commenter described less fatigue, more enjoyment, calmer focus and deeper sleep over five days, alongside blue-green urine and an unpleasant taste.
Reported use in this account
- Product
- Product described as methylene blue
- Amount
- 4 mg
- Frequency
- Not specified clearly
- Route
- Oral
- Duration
- Five days at the report
Other exposures described: Earlier psilocybin exposure
The short, unverified account and prior psilocybin exposure do not establish antidepressant efficacy or longer-term safety.
Read the original accountSleep: reported experiences
Calmer mood, clearer thinking and deeper sleep
A separate commenter described less fatigue, more enjoyment, calmer focus and deeper sleep over five days, alongside blue-green urine and an unpleasant taste.
Reported use in this account
- Product
- Product described as methylene blue
- Amount
- 4 mg
- Frequency
- Not specified clearly
- Route
- Oral
- Duration
- Five days at the report
Other exposures described: Earlier psilocybin exposure
The short, unverified account and prior psilocybin exposure do not establish antidepressant efficacy or longer-term safety.
Read the original accountPanic and poor sleep
A person with long COVID symptoms and hyperthyroidism described panic, persistent distress and worsened sleep after a methylene-blue exposure.
Reported use in this account
- Product
- Methylene-blue drops described by the author as a 1% product
- Amount
- 1 mg in two drops, as reported by the author; strength not independently verified
- Frequency
- One described exposure
- Route
- Not specified clearly
- Duration
- One exposure, with symptoms reported six days later
Other exposures described: Propranolol; Long COVID symptoms and hyperthyroidism; Activated charcoal taken after the reaction
Pre-existing illness, propranolol exposure and product uncertainty complicate attribution. Duration and cause were not medically verified.
Read the original accountMood: reported experiences
Calmer mood, clearer thinking and deeper sleep
A separate commenter described less fatigue, more enjoyment, calmer focus and deeper sleep over five days, alongside blue-green urine and an unpleasant taste.
Reported use in this account
- Product
- Product described as methylene blue
- Amount
- 4 mg
- Frequency
- Not specified clearly
- Route
- Oral
- Duration
- Five days at the report
Other exposures described: Earlier psilocybin exposure
The short, unverified account and prior psilocybin exposure do not establish antidepressant efficacy or longer-term safety.
Read the original accountPanic and poor sleep
A person with long COVID symptoms and hyperthyroidism described panic, persistent distress and worsened sleep after a methylene-blue exposure.
Reported use in this account
- Product
- Methylene-blue drops described by the author as a 1% product
- Amount
- 1 mg in two drops, as reported by the author; strength not independently verified
- Frequency
- One described exposure
- Route
- Not specified clearly
- Duration
- One exposure, with symptoms reported six days later
Other exposures described: Propranolol; Long COVID symptoms and hyperthyroidism; Activated charcoal taken after the reaction
Pre-existing illness, propranolol exposure and product uncertainty complicate attribution. Duration and cause were not medically verified.
Read the original accountMood improved after an earlier anxious reaction
An author described anxiety during combined methylene-blue and duloxetine exposure, then a perceived improvement in anxiety and mood after changing medicines; lisdexamfetamine was also involved.
Reported use in this account
- Product
- Product described as methylene blue
- Amount
- 70 mg for the evening exposure described after changing medicines
- Frequency
- Evening use; ongoing frequency not stated
- Route
- Not specified clearly
- Duration
- Three days after restarting at the initial report
Other exposures described: Recently tapered and stopped duloxetine; Lisdexamfetamine; Earlier combined methylene-blue/duloxetine exposure
Recent antidepressant changes and concurrent stimulant treatment prevent attribution. This account does not demonstrate a safe interval between medicines or a safe combination.
Read the original accountFocus: reported experiences
Calmer mood, clearer thinking and deeper sleep
A separate commenter described less fatigue, more enjoyment, calmer focus and deeper sleep over five days, alongside blue-green urine and an unpleasant taste.
Reported use in this account
- Product
- Product described as methylene blue
- Amount
- 4 mg
- Frequency
- Not specified clearly
- Route
- Oral
- Duration
- Five days at the report
Other exposures described: Earlier psilocybin exposure
The short, unverified account and prior psilocybin exposure do not establish antidepressant efficacy or longer-term safety.
Read the original accountApproval status
ProvayBlue is FDA approved for acquired methemoglobinemia in pediatric and adult patients. Cognitive enhancement, anti-aging, and consumer oral preparations are not covered by that indication.
Approved uses
- ProvayBlue: acquired methemoglobinemia in pediatric and adult patients
Approved for acquired methemoglobinemia
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Durable cognitive or functional benefit
- Safety of repeated wellness exposure
- Whether research preparations resemble products encountered online
Summary
Methylene blue is a medically active drug with a narrow approved use; its interactions matter more than confident online nootropic claims suggest.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- nihDailyMed: ProvayBlue prescribing information
Current official label, approved indication, boxed warning, contraindications, and adverse reactions.
- pubmedMethylene blue, functional imaging, and memory
26-person randomized experiment; short-term task and imaging outcomes.
- pubmedMethylene blue and fear-extinction learning
42-person claustrophobia experiment; outcomes depended on successful versus unsuccessful exposure learning.